Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP Operations | February 03, 2004 | February 04, 2004 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 03, 2004 · Filed February 04, 2004
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 203,772 |
Reported balance
After 2004-02-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2004-02-03 · Exercise / conversion · Acquired 9,716 · Balance 203,772 |
| Common StockSEC Table I · non-derivative | Direct | 243,772 |
Reported balance
After 2004-02-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2004-02-03 · Exercise / conversion · Acquired 40,000 · Balance 243,772 |
| Common StockSEC Table I · non-derivative | Direct | 246,056 |
Reported balance
After 2004-02-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2004-02-03 · Exercise / conversion · Acquired 2,284 · Balance 246,056 |
| Common StockSEC Table I · non-derivative | Direct | 238,556 |
Reported balance
After 2004-02-03 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2004-02-03 · Sale · Disposed 7,500 · Balance 238,556 |
| Common StockSEC Table I · non-derivative | Direct | 226,056 |
Reported balance
After 2004-02-03 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2004-02-03 · Sale · Disposed 12,500 · Balance 226,056 |
| Common StockSEC Table I · non-derivative | Direct | 211,056 |
Reported balance
After 2004-02-03 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2004-02-03 · Sale · Disposed 15,000 · Balance 211,056 |
| Common StockSEC Table I · non-derivative | Direct | 206,056 |
Reported balance
After 2004-02-03 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2004-02-03 · Sale · Disposed 5,000 · Balance 206,056 |
| Common StockSEC Table I · non-derivative | Direct | 201,056 |
Reported balance
After 2004-02-03 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2004-02-03 · Sale · Disposed 5,000 · Balance 201,056 |
| Common StockSEC Table I · non-derivative | Direct | 196,340 |
Reported balance
After 2004-02-03 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2004-02-03 · Sale · Disposed 4,716 · Balance 196,340 |
| Common StockSEC Table I · non-derivative | Direct | 196,040 |
Reported balance
After 2004-02-03 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2004-02-03 · Gift · Disposed 300 · Balance 196,040 F1: Represents transfer of shares to son under Uniform Gift to Minors Act. F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. |
| Common StockSEC Table I · non-derivative | Indirectby Son | 5,600 |
Reported balance
After 2004-02-03 transaction · row 11
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 11 · 2004-02-03 · Gift · Acquired 300 · Balance 5,600 F1: Represents transfer of shares to son under Uniform Gift to Minors Act. F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.59 · Expires 2009-07-22 | Direct | 4,568 |
Reported balance
After 2004-02-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2004-02-03 · Exercise / conversion · Disposed 2,284 · Balance 4,568 F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.59 · Expires 2009-07-22 | Direct | 19,432 |
Reported balance
After 2004-02-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2004-02-03 · Exercise / conversion · Disposed 9,716 · Balance 19,432 F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.81 · Expires 2010-04-05 | Direct | 53,252 |
Reported balance
After 2004-02-03 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2004-02-03 · Exercise / conversion · Disposed 40,000 · Balance 53,252 F3: Options, split into incentive and non-qualified stock options, vest 20% on 4/05/2001, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 4/05/2005. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents transfer of shares to son under Uniform Gift to Minors Act.
F2: Options, split into incentive and non-qualified stock options, vest 20% on 7/22/2000, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 7/22/2004.
F3: Options, split into incentive and non-qualified stock options, vest 20% on 4/05/2001, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 4/05/2005.
F4: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Global Blood Therapeutics, Inc.
Report date October 05, 2022 · Filed October 06, 2022
Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 1
1 source rowRow 1 · 2022-10-05 · Disposition to issuer · Disposed 37,865 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.30 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-05 · Disposition to issuer · Disposed 7,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 | Direct | 0 |
Reported balance
After 2022-10-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
MyoKardia, Inc.
Report date November 17, 2020 · Filed November 19, 2020
Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 1
1 source rowRow 1 · 2020-11-17 · Other · Disposed 29,508 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-17 · Disposition to issuer · Disposed 21,800 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.85 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.77 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-17 · Disposition to issuer · Disposed 6,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.27 | Direct | 0 |
Reported balance
After 2020-11-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-17 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
NVIDIA CORP
Report date June 26, 2024 · Filed June 26, 2024
Section 16 reporting ended · disclosed 2024-06-26. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2024 Filed Apr 3, 2024 20:27 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 7,000 | $887.89 | $6,215,259.40 |
DisclosureSEC source: 0001045810-24-000090 · wk-form4_1712176010.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 116,000 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $887.57 to $888.32. The Reporting Person will provide upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:06 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 15,000 | $796.45 | $11,946,691.50 |
DisclosureSEC source: 0001045810-24-000040 · wk-form4_1709071584.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 123,000 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $796.00 to $796.77. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 22:24 UTC | NVIDIA CORP NVDA · Entity 1023 | GrantCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001045810-23-000154 · wk-form4_1687904630.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,612 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 15, 2023 and 50% of the shares on May 15, 2024. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document |
| May 26, 2023 Filed May 31, 2023 21:15 UTC | NVIDIA CORP NVDA · Entity 1023 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001045810-23-000099 · wk-form4_1685567697.xml · nonDerivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Taylor William Perry 2023 Irrevocable Trust Disclosed balance after: 1,000 F1 · price: Gift without consideration. F4 · ownership.nature: The shares are held by The Taylor William Perry 2023 Irrevocable Trust, of which the Reporting Person is a trustee. Mr. Perry disclaims beneficial ownership of the shares held by the trust except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 26, 2023 Filed May 31, 2023 21:15 UTC | NVIDIA CORP NVDA · Entity 1023 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001045810-23-000099 · wk-form4_1685567697.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Zoe Blue Perry 2020 Irrevocable Trust Disclosed balance after: 1,000 F1 · price: Gift without consideration. F3 · ownership.nature: The shares are held by The Zoe Blue Perry 2020 Irrevocable Trust, of which the Reporting Person is a trustee. Mr. Perry disclaims beneficial ownership of the shares held by the trust except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 26, 2023 Filed May 31, 2023 21:15 UTC | NVIDIA CORP NVDA · Entity 1023 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001045810-23-000099 · wk-form4_1685567697.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 138,000 F1 · price: Gift without consideration. F2 · ownership.nature: Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:59 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 1,400 | $238.00 | $333,195.52 |
DisclosureSEC source: 0001045810-23-000024 · wf-form4_167762152866810.xml · nonDerivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 140,000 F5 · price: Represents weighted average sales price. The shares were sold at prices ranging from $237.79 to $238.32. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:59 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 5,700 | $237.36 | $1,352,977.08 |
DisclosureSEC source: 0001045810-23-000024 · wf-form4_167762152866810.xml · nonDerivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 141,400 F4 · price: Represents weighted average sales price. The shares were sold at prices ranging from $236.78 to $237.76. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:59 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 6,100 | $236.25 | $1,441,154.89 |
DisclosureSEC source: 0001045810-23-000024 · wf-form4_167762152866810.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 147,100 F3 · price: Represents weighted average sales price. The shares were sold at prices ranging from $235.78 to $236.75. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:59 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 6,800 | $235.31 | $1,600,100.52 |
DisclosureSEC source: 0001045810-23-000024 · wf-form4_167762152866810.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 153,200 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $234.78 to $235.76. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:21 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,600 | Not disclosed Strike: $22.30 | Not disclosed |
DisclosureSEC source: 0000899243-22-033162 · doc4.xml · derivative · entry 7 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,600 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:21 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,600 | Not disclosed Strike: $37.09 | Not disclosed |
DisclosureSEC source: 0000899243-22-033162 · doc4.xml · derivative · entry 6 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,600 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:21 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,247 | Not disclosed Strike: $64.75 | Not disclosed |
DisclosureSEC source: 0000899243-22-033162 · doc4.xml · derivative · entry 5 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,247 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:21 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $56.30 | Not disclosed |
DisclosureSEC source: 0000899243-22-033162 · doc4.xml · derivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:21 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $42.25 | Not disclosed |
DisclosureSEC source: 0000899243-22-033162 · doc4.xml · derivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:21 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerRestricted Stock Units · Derivative | 3,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033162 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration. Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 16:21 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Disposition to issuerCommon Stock | 37,865 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033162 · doc4.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 18:38 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-022903 · doc4.xml · derivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 18:38 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 5,600 | $0.00 Strike: $22.30 | $0.00 |
DisclosureSEC source: 0000899243-22-022903 · doc4.xml · derivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2032-06-13 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 18:38 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-022903 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 14, 2022. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 14, 2022. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 18:38 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 3,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-022903 · doc4.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 22:16 UTC | NVIDIA CORP NVDA · Entity 1023 | GrantCommon Stock | 1,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001045810-22-000105 · wf-form4_165464016506276.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,962 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 16, 2022 and 50% of the shares on May 17, 2023. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 22:16 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 100 | $265.49 | $26,549.00 |
DisclosureSEC source: 0001045810-22-000052 · wf-form4_164790097817404.xml · nonDerivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,524 Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 22:16 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 2,716 | $264.92 | $719,522.72 |
DisclosureSEC source: 0001045810-22-000052 · wf-form4_164790097817404.xml · nonDerivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,624 F4 · price: Represents weighted average sales price. The shares were sold at prices ranging from $264.43 to $265.36. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 22:16 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 12,100 | $263.67 | $3,190,407.00 |
DisclosureSEC source: 0001045810-22-000052 · wf-form4_164790097817404.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,340 F3 · price: Represents weighted average sales price. The shares were sold at prices ranging from $263.32 to $264.21. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 22:16 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 1,800 | $262.90 | $473,220.00 |
DisclosureSEC source: 0001045810-22-000052 · wf-form4_164790097817404.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,440 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $262.30 to $263.25 The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Adjusted to reflect a four-for-one forward split of the Issuer's common stock in the form of a stock dividend distributed on July 19, 2021 (the "stock split"). Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-024985 · doc4.xml · derivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 5,600 | $0.00 Strike: $37.09 | $0.00 |
DisclosureSEC source: 0000899243-21-024985 · doc4.xml · derivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2031-06-16 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 3,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-024985 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 17, 2021. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 17, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:27 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 3,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-024985 · doc4.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:10 UTC | NVIDIA CORP NVDA · Entity 1023 | GrantCommon Stock | 429 | $0.00 | $0.00 |
DisclosureSEC source: 0001045810-21-000092 · wf-form4_162318296467604.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,060 F1 · price: Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 214 of the shares on November 17, 2021 and 215 of the shares on May 18, 2022. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:55 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 1,400 | $556.98 | $779,772.00 |
DisclosureSEC source: 0001045810-21-000041 · wf-form4_161774248584354.xml · nonDerivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,631 F2 · price: Represents weighted average sales price. The shares were sold at prices ranging from $556.92 to $557.00. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:55 UTC | NVIDIA CORP NVDA · Entity 1023 | SaleCommon Stock | 4,704 | $556.46 | $2,617,587.84 |
DisclosureSEC source: 0001045810-21-000041 · wf-form4_161774248584354.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,031 F1 · price: Represents weighted average sales price. The shares were sold at prices ranging from $555.90 to $556.88. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:19 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Disposition to issuerStock Option (Right to buy) · Derivative | 3,000 | Not disclosed Strike: $100.27 | Not disclosed |
DisclosureSEC source: 0000899243-20-031755 · doc4.xml · derivative · entry 7 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:19 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Disposition to issuerStock Option (Right to buy) · Derivative | 6,600 | Not disclosed Strike: $47.77 | Not disclosed |
DisclosureSEC source: 0000899243-20-031755 · doc4.xml · derivative · entry 6 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,600 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:19 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Disposition to issuerStock Option (Right to buy) · Derivative | 11,000 | Not disclosed Strike: $48.85 | Not disclosed |
DisclosureSEC source: 0000899243-20-031755 · doc4.xml · derivative · entry 5 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:19 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Disposition to issuerStock Option (Right to buy) · Derivative | 11,000 | Not disclosed Strike: $14.00 | Not disclosed |
DisclosureSEC source: 0000899243-20-031755 · doc4.xml · derivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:19 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Disposition to issuerStock Option (Right to buy) · Derivative | 11,000 | Not disclosed Strike: $13.60 | Not disclosed |
DisclosureSEC source: 0000899243-20-031755 · doc4.xml · derivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:19 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Disposition to issuerStock Option (Right to buy) · Derivative | 21,800 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0000899243-20-031755 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,800 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 20:19 UTC | MyoKardia, Inc. MYOK · Entity 145206 | OtherCommon Stock | 29,508 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031755 · doc4.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 18:59 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017418 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 18:59 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $100.27 | $0.00 |
DisclosureSEC source: 0000899243-20-017418 · doc4.xml · derivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments after June 18, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:33 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantRestricted Stock Units · Derivative | 3,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017318 · doc4.xml · derivative · entry 4 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,037 Underlying: Common Stock · 3,037 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:33 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | GrantStock Option (Right to Buy) · Derivative | 5,247 | $0.00 Strike: $64.75 | $0.00 |
DisclosureSEC source: 0000899243-20-017318 · doc4.xml · derivative · entry 3 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,247 Underlying: Common Stock · 5,247 shares Expires 2030-06-16 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2020 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:33 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionRestricted Stock Units · Derivative | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017318 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:33 UTC | Global Blood Therapeutics, Inc. GBT · Entity 123220 | Exercise / conversionCommon Stock | 4,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017318 · doc4.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 13, 2020 Filed Jun 16, 2020 18:03 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionRestricted Stock Units · Derivative | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-016682 · doc4.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 13, 2020 Filed Jun 16, 2020 18:03 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-016682 · doc4.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: RSUs convert into common stock on a one-for-one basis. Read SEC document |
| June 13, 2020 Filed Jun 23, 2020 18:25 UTC Amendment | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionRestricted Stock Units · Derivative | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017508 · doc4a.xml · derivative · entry 2 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document |
| June 13, 2020 Filed Jun 23, 2020 18:25 UTC Amendment | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 2,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017508 · doc4a.xml · nonDerivative · entry 1 PERRY MARK L · CIK 0001190270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: RSUs convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.